These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23762971)

  • 1. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
    Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
    J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-failure gout: a moving target.
    Edwards NL
    Arthritis Rheum; 2008 Sep; 58(9):2587-90. PubMed ID: 18759307
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment failure gout.
    Ali S; Lally EV
    Med Health R I; 2009 Nov; 92(11):369-71. PubMed ID: 19999896
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical inquiry: Which prophylactic therapies best prevent gout attacks?
    White S; Mounsey A; Tillett J
    J Fam Pract; 2014 Apr; 63(4):216, 221. PubMed ID: 24905127
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of gout.
    Meltzler M
    BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24493155
    [No Abstract]   [Full Text] [Related]  

  • 18. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
    Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Needle or Knife: Pegloticase for Refractory Crippling Gout in a Nonagenarian.
    Choi N; Eickhoff J; Keith M
    J Clin Rheumatol; 2017 Sep; 23(6):343. PubMed ID: 28816765
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for uricase in gout.
    Pay S; Terkeltaub AR
    Curr Rheumatol Rep; 2003 Jun; 5(3):213-4. PubMed ID: 12744813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.